Significance of High Trough Concentration of Teicoplanin in the Treatment of Methicillin-Resistant Staphylococcus aureus Infection.
BACKGROUND
Teicoplanin (TEIC) is a glycopeptide currently used for the treatment of methicillin-resistant Staphylococcus aureus (MRSA). A plasma trough concentration (Cmin) of >20 mg/l should be used for severe infections. The aim of this study was to assess the efficacy, safety and use of Cmin >20 mg/l on day 4-6 in patients with complicated MRSA infections.


METHODS
Blood samples were drawn from the 41 included patients just before TEIC administration between day 4 and 6. The patients were divided into three groups (group A: >20 mg/l, group B: 10-20 mg/l and group C: <10 mg/l) based on their Cmin on day 4-6.


RESULTS
Differences in efficacy between the groups were significant, but differences in safety were not. The patients in group A required lower cumulative doses than those in either groups B or C.


CONCLUSIONS
The optimal clinical efficacy and safety might be associated with TEIC Cmin on the fourth to sixth day.
Department of Clinical Pharmacy, Oita University Hospital, Yufu, Japan.
Yuhki
Y
Sato
Issei
I
Tokimatsu
Yosuke
Y
Suzuki
Hiroki
H
Itoh
Kazufumi
K
Hiramatsu
Jun-ichi
J
Kadota
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000097:blood* / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D008875:Middle Aged; D012189:Retrospective Studies; D013203:Staphylococcal Infections / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy; D017334:Teicoplanin / Q000097:blood* / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D017334:Teicoplanin